ATTR-CM Indication Strategy Report 2026: TTR, Trials and $310M Deal Signal uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Hypertrophic Cardiomyopathy Indication Strategy Report 2026: Cardiac Myosin, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

HFrEF Indication Strategy Report 2026: SGLT2, AT1R, Trials and Competitive Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

HFpEF Indication Strategy Report 2026: SGLT2, MR, Trials and Deal Signals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Pulmonary Arterial Hypertension Indication Strategy Report 2026: BMPR2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Elevated Lipoprotein(a) Indication Strategy Report 2026: LPA, Trials and Market Opportunity uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Severe Hypertriglyceridemia Indication Strategy Report 2026: APOC3, ANGPTL3 and Trials uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Familial Hypercholesterolemia Indication Strategy Report 2026: PCSK9, LDLR, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Type 1 Diabetes Indication Strategy Report 2026: CD3, Cell Therapy, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Type 2 Diabetes Indication Strategy Report 2026: GLP-1R, SGLT2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Adult Obesity Indication Strategy Report 2026: GLP-1R, GIPR, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Liver Transplant Rejection Indication Strategy Report 2026: CD40, Trials and Market Signals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.